Do analysts rate AVCT or SCLP?

Avacta Group presently has a consensus target price of GBX 99, suggesting a potential upside of 45.59%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts clearly believe Avacta Group is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avacta Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, AVCT or SCLP?

Scancell has higher revenue and earnings than Avacta Group. Scancell is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avacta Group £113K 2,819.58 -£30.08M -£9.66 N/A Scancell £4.71M 21.59 -£6.75M -£0.55 N/A

Is AVCT or SCLP more profitable?

Scancell has a net margin of -116.98% compared to Avacta Group's net margin of -33,961.06%. Scancell's return on equity of 90.29% beat Avacta Group's return on equity. Company Net Margins Return on Equity Return on Assets Avacta Group -33,961.06% -2,929.47% -21.80% Scancell -116.98% 90.29% -45.28%

Do analysts prefer PRTC or SCLP?

PureTech Health presently has a consensus price target of GBX 508, indicating a potential upside of 341.74%. Given PureTech Health's stronger consensus rating and higher probable upside, equities analysts plainly believe PureTech Health is more favorable than Scancell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Scancell 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PRTC or SCLP more profitable?

Scancell has a net margin of -116.98% compared to PureTech Health's net margin of -2,355.32%. Scancell's return on equity of 90.29% beat PureTech Health's return on equity. Company Net Margins Return on Equity Return on Assets PureTech Health -2,355.32% -31.98% -13.39% Scancell -116.98% 90.29% -45.28%

Scancell (SCLP) Competitors

GBX 9.80 +0.01 (+0.12%)

As of 08:14 AM Eastern

Compare

SCLP vs. AVCT, HZD, PRTC, VRP, and ARIX

Should you buy Scancell stock or one of its competitors? MarketBeat compares Scancell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scancell include Avacta Group (AVCT), Horizon Discovery Group plc (HZD.L) (HZD), PureTech Health (PRTC), Verona Pharma plc (VRP.L) (VRP), and Arix Bioscience (ARIX). These companies are all part of the "biotechnology" industry.

How does Scancell compare to Avacta Group?

Avacta Group (LON:AVCT) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Avacta Group presently has a consensus target price of GBX 99, suggesting a potential upside of 45.59%. Given Avacta Group's stronger consensus rating and higher possible upside, analysts clearly believe Avacta Group is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Avacta Group has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Scancell has a beta of 0.736, meaning that its stock price is 26% less volatile than the broader market.

3.1% of Avacta Group shares are held by institutional investors. Comparatively, 1.5% of Scancell shares are held by institutional investors. 47.7% of Avacta Group shares are held by insiders. Comparatively, 15.5% of Scancell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Scancell has higher revenue and earnings than Avacta Group. Scancell is trading at a lower price-to-earnings ratio than Avacta Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avacta Group	£113K	2,819.58	-£30.08M	-£9.66	N/A
Scancell	£4.71M	21.59	-£6.75M	-£0.55	N/A

Scancell has a net margin of -116.98% compared to Avacta Group's net margin of -33,961.06%. Scancell's return on equity of 90.29% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avacta Group	-33,961.06%	-2,929.47%	-21.80%
Scancell	-116.98%	90.29%	-45.28%

In the previous week, Avacta Group had 1 more articles in the media than Scancell. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Scancell. Avacta Group's average media sentiment score of 0.75 beat Scancell's score of 0.18 indicating that Avacta Group is being referred to more favorably in the media.

Company	Overall Sentiment
Avacta Group	Positive
Scancell	Neutral

Summary

Avacta Group beats Scancell on 11 of the 16 factors compared between the two stocks.

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) (LON:HZD) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Horizon Discovery Group plc (HZD.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A
Scancell	-116.98%	90.29%	-45.28%

1.5% of Scancell shares are held by institutional investors. 15.5% of Scancell shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Horizon Discovery Group plc (HZD.L) has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Horizon Discovery Group plc (HZD.L)	£54.63M	0.00	N/A	-£5.50	N/A
Scancell	£4.71M	21.59	-£6.75M	-£0.55	N/A

In the previous week, Scancell's average media sentiment score of 0.18 beat Horizon Discovery Group plc (HZD.L)'s score of 0.00 indicating that Scancell is being referred to more favorably in the news media.

Company	Overall Sentiment
Horizon Discovery Group plc (HZD.L)	Neutral
Scancell	Neutral

Summary

Scancell beats Horizon Discovery Group plc (HZD.L) on 6 of the 9 factors compared between the two stocks.

How does Scancell compare to PureTech Health?

PureTech Health (LON:PRTC) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

PureTech Health has a beta of 0.793, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Scancell has a beta of 0.736, meaning that its stock price is 26% less volatile than the broader market.

In the previous week, PureTech Health had 11 more articles in the media than Scancell. MarketBeat recorded 11 mentions for PureTech Health and 0 mentions for Scancell. PureTech Health's average media sentiment score of 1.35 beat Scancell's score of 0.18 indicating that PureTech Health is being referred to more favorably in the media.

Company	Overall Sentiment
PureTech Health	Positive
Scancell	Neutral

PureTech Health presently has a consensus price target of GBX 508, indicating a potential upside of 341.74%. Given PureTech Health's stronger consensus rating and higher probable upside, equities analysts plainly believe PureTech Health is more favorable than Scancell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Scancell	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Scancell has a net margin of -116.98% compared to PureTech Health's net margin of -2,355.32%. Scancell's return on equity of 90.29% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Scancell	-116.98%	90.29%	-45.28%

Scancell has higher revenue and earnings than PureTech Health. Scancell is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	60.08	-£91.86M	-£46.00	N/A
Scancell	£4.71M	21.59	-£6.75M	-£0.55	N/A

33.5% of PureTech Health shares are owned by institutional investors. Comparatively, 1.5% of Scancell shares are owned by institutional investors. 13.3% of PureTech Health shares are owned by insiders. Comparatively, 15.5% of Scancell shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

PureTech Health beats Scancell on 10 of the 16 factors compared between the two stocks.

How does Scancell compare to Verona Pharma plc (VRP.L)?

Scancell (LON:SCLP) and Verona Pharma plc (VRP.L) (LON:VRP) are related small-cap companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Verona Pharma plc (VRP.L) has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Verona Pharma plc (VRP.L)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scancell	-116.98%	90.29%	-45.28%
Verona Pharma plc (VRP.L)	N/A	N/A	N/A

1.5% of Scancell shares are held by institutional investors. 15.5% of Scancell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Scancell's average media sentiment score of 0.18 beat Verona Pharma plc (VRP.L)'s score of 0.00 indicating that Scancell is being referred to more favorably in the media.

Company	Overall Sentiment
Scancell	Neutral
Verona Pharma plc (VRP.L)	Neutral

Verona Pharma plc (VRP.L) has lower revenue, but higher earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Verona Pharma plc (VRP.L), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scancell	£4.71M	21.59	-£6.75M	-£0.55	N/A
Verona Pharma plc (VRP.L)	N/A	N/A	N/A	-£32.70	N/A

Summary

Scancell beats Verona Pharma plc (VRP.L) on 6 of the 9 factors compared between the two stocks.

How does Scancell compare to Arix Bioscience?

Arix Bioscience (LON:ARIX) and Scancell (LON:SCLP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Arix Bioscience has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Scancell has a beta of 0.736, indicating that its share price is 26% less volatile than the broader market.

41.3% of Arix Bioscience shares are held by institutional investors. Comparatively, 1.5% of Scancell shares are held by institutional investors. 20.7% of Arix Bioscience shares are held by company insiders. Comparatively, 15.5% of Scancell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Scancell's average media sentiment score of 0.18 beat Arix Bioscience's score of 0.00 indicating that Scancell is being referred to more favorably in the news media.

Company	Overall Sentiment
Arix Bioscience	Neutral
Scancell	Neutral

Arix Bioscience has higher revenue and earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A
Scancell	£4.71M	21.59	-£6.75M	-£0.55	N/A

Arix Bioscience has a net margin of 105.64% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Arix Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arix Bioscience	105.64%	6.41%	2.18%
Scancell	-116.98%	90.29%	-45.28%

Summary

Arix Bioscience beats Scancell on 9 of the 11 factors compared between the two stocks.

Get Scancell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCLP vs. The Competition

Export

Metric	Scancell	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£101.70M	£3.51B	£6.81B	£2.83B
Dividend Yield	N/A	3.78%	2.59%	6.15%
P/E Ratio	-17.82	7.39	282.12	368.44
Price / Sales	21.59	1,209.27	573.08	83,484.29
Price / Cash	7.86	44.80	28.60	27.89
Price / Book	-25.14	16.98	11.02	7.09
Net Income	-£6.75M	-£12.56M	£3.49B	£5.89B
7 Day Performance	1.66%	-1.85%	0.47%	6.25%
1 Month Performance	-31.23%	-8.52%	-4.24%	0.13%
1 Year Performance	-6.62%	47.51%	62.63%	64.12%

Scancell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCLP Scancell	N/A	GBX 9.80 +0.1%	N/A	-6.7%	£101.70M	£4.71M	N/A	51
AVCT Avacta Group	2.2162 of 5 stars	GBX 68.50 -0.7%	GBX 99 +44.5%	+39.6%	£320.96M	£113K	N/A	120
HZD Horizon Discovery Group plc (HZD.L)	N/A	N/A	N/A	N/A	£302.98M	£54.63M	N/A	416
PRTC PureTech Health	3.4551 of 5 stars	GBX 124 +0.5%	GBX 508 +309.7%	-13.7%	£301.84M	£4.66M	N/A	300	News Coverage Gap Down
VRP Verona Pharma plc (VRP.L)	N/A	N/A	N/A	N/A	£228M	N/A	N/A	22	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:SCLP) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scancell (SCLP) Competitors

SCLP vs. AVCT, HZD, PRTC, VRP, and ARIX

How does Scancell compare to Avacta Group?

Summary

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Summary

How does Scancell compare to PureTech Health?

Summary

How does Scancell compare to Verona Pharma plc (VRP.L)?

Summary

How does Scancell compare to Arix Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLP vs. The Competition

Scancell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scancell (SCLP) Competitors

SCLP vs. AVCT, HZD, PRTC, VRP, and ARIX

How does Scancell compare to Avacta Group?

Do analysts rate AVCT or SCLP?

Which has more volatility & risk, AVCT or SCLP?

Do insiders and institutionals hold more shares of AVCT or SCLP?

Which has higher earnings & valuation, AVCT or SCLP?

Is AVCT or SCLP more profitable?

Does the media favor AVCT or SCLP?

Summary

How does Scancell compare to Horizon Discovery Group plc (HZD.L)?

Is HZD or SCLP more profitable?

Do institutionals and insiders have more ownership in HZD or SCLP?

Which has preferable valuation & earnings, HZD or SCLP?

Does the media prefer HZD or SCLP?

Summary

How does Scancell compare to PureTech Health?

Which has more risk & volatility, PRTC or SCLP?

Does the media prefer PRTC or SCLP?

Do analysts prefer PRTC or SCLP?

Is PRTC or SCLP more profitable?

Which has stronger valuation & earnings, PRTC or SCLP?

Do institutionals & insiders believe in PRTC or SCLP?

Summary

How does Scancell compare to Verona Pharma plc (VRP.L)?

Is SCLP or VRP more profitable?

Do insiders & institutionals have more ownership in SCLP or VRP?

Does the media prefer SCLP or VRP?

Which has higher valuation & earnings, SCLP or VRP?

Summary

How does Scancell compare to Arix Bioscience?

Which has more risk & volatility, ARIX or SCLP?

Do insiders & institutionals have more ownership in ARIX or SCLP?

Does the media refer more to ARIX or SCLP?

Which has higher earnings and valuation, ARIX or SCLP?

Is ARIX or SCLP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCLP vs. The Competition

Scancell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools